RESUMO
OBJECTIVES: To review medical malpractice trends and to identify the most common claims filed against medical providers for the management of patients with priapism. METHODS: Using the Westlaw legal database, a search was done for the keyword "priapism" between July 1, 1980 and July 1, 2020. Cases were evaluated for plaintiff demographics, reasons for filing claims, management outcomes, legal verdicts and awards and further categorized based upon the timing of the alleged malpractice. RESULTS: Alleged negligence during the pre-management period was cited in 30 cases. Administration of psychotropic medications was the most common reasons for filing pre-management claims 22/56 (39.3%). Delay in care accounted for 18/56 (32.1%) and complications of surgery were 5/56 (8.9%) of claims. The majority of the completed cases were in favor of the defendants (39/47; 83.0%). There was no association between type of health care provider or timing of alleged malpractice and ultimate verdict. CONCLUSIONS: Prescribing psychoactive medications without warning of the adverse effect profile is the most common reason for claims filed against providers with trazodone as the leading medication. Medical providers should ensure that patients are well informed of this adverse effect prior to prescription. Regardless, the majority of medical malpractice cases carry a verdict in favor of the defendant.
Assuntos
Disfunção Erétil , Imperícia , Priapismo , Psicotrópicos , Disfunção Erétil/epidemiologia , Disfunção Erétil/terapia , Humanos , Revisão da Utilização de Seguros , Masculino , Imperícia/legislação & jurisprudência , Imperícia/tendências , Priapismo/epidemiologia , Priapismo/terapia , Psicotrópicos/administração & dosagem , Psicotrópicos/efeitos adversos , Trazodona/administração & dosagem , Trazodona/efeitos adversos , Estados UnidosAssuntos
Prescrições de Medicamentos/estatística & dados numéricos , Padrões de Prática Médica/tendências , Medicamentos Indutores do Sono/uso terapêutico , Trazodona/uso terapêutico , Zolpidem/uso terapêutico , Adulto , Feminino , Planos de Assistência de Saúde para Empregados , Humanos , Seguro de Saúde (Situações Limítrofes) , Masculino , Trazodona/administração & dosagem , Estados UnidosRESUMO
OBJECTIVE: The purpose of this study was to describe the prescribing practices of clinicians for patients with major depressive disorder (MDD). METHODS: This population-based, descriptive study of insured patients (N=54,107) identified people who were 18 years or older, had a claim for MDD, had at least one prescription for an antidepressant medication in 2013, and had continuous insurance coverage during the study period. Prescription claims were evaluated to determine the most commonly prescribed antidepressant medication and most common dose. RESULTS: The three most commonly prescribed antidepressant medications were citalopram (N=11,995, 22.2%), sertraline (N=10,791, 19.9%), and trazodone (N=9,501, 17.6%). The most common daily doses were 20 mg citalopram (N=6,304, 52.6%), 50 mg sertraline (N=4,173, 38.7%), and 100 mg trazodone (N=3,220, 33.9%). CONCLUSIONS: This is the first report of its kind that provides drug- and dosage-level details to demonstrate that antidepressant prescribing in clinical practice is largely within recommended guidelines.
Assuntos
Antidepressivos/uso terapêutico , Citalopram/uso terapêutico , Transtorno Depressivo Maior/tratamento farmacológico , Prescrições de Medicamentos/estatística & dados numéricos , Seguro Saúde/estatística & dados numéricos , Padrões de Prática Médica/estatística & dados numéricos , Sertralina/uso terapêutico , Trazodona/uso terapêutico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antidepressivos/administração & dosagem , Citalopram/administração & dosagem , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Sertralina/administração & dosagem , Trazodona/administração & dosagem , Estados Unidos , Adulto JovemRESUMO
BACKGROUND: Antidepressants have been shown to be efficacious for the treatment of pediatric depression. However, many youths do not receive an adequate duration of treatment, and factors associated with nonadherence in this population remain poorly understood. OBJECTIVE: To examine rates of antidepressant adherence for depressed youth and identify factors associated with adherence during the acute and continuation phases of treatment. METHODS: A retrospective cohort analysis was conducted using claims data from a state Medicaid-enrolled population of 1650 youths (aged 5-17 years) with new episodes of depression between January 1, 2005, and December 30, 2007. These patients were treated with selective serotonin reuptake inhibitors or newer antidepressants and followed for 6 months from the first prescription fill date. Adherence measures were derived from the Health Plan Employer Data and Information Set (HEDIS) quality indicators on antidepressant management (3 months of continuous treatment for the acute phase and 6 months for the continuation phase) and assessed using the medication possession ratio. Multivariate logistic regression analyses evaluated the association between demographic, clinical, medication, and treatment factors, and adherence. RESULTS: About half (49.5%) of the youths were adherent to antidepressant medication during the acute phase, and 42% of these were adherent during the continuation phase; 21% were adherent across both treatment phases. Optimal follow-up visits and adequate antidepressant dosing was associated with better adherence during both treatment phases, as was use of other psychotropic medications. Youths prescribed trazodone for sleep had higher adherence rates during the acute phase. Minority youths and adolescents had lower adherence rates during the acute phase. Youths in foster care had higher adherence rates during both treatment phases. CONCLUSIONS: Nonadherence with antidepressant medications is common among Medicaid-covered children and adolescents. Study findings underscore the need for clinicians to deliver guideline-concordant care, assess adherence, and develop interventions that improve adherence, particularly for vulnerable subgroups.
Assuntos
Antidepressivos/administração & dosagem , Depressão/tratamento farmacológico , Medicaid , Adesão à Medicação , Adolescente , Antidepressivos/uso terapêutico , Criança , Pré-Escolar , Bases de Dados Factuais , Depressão/prevenção & controle , Feminino , Cuidados no Lar de Adoção , Humanos , Estudos Longitudinais , Masculino , Adesão à Medicação/etnologia , Ohio , Guias de Prática Clínica como Assunto , Indicadores de Qualidade em Assistência à Saúde , Prevenção Secundária , Inibidores Seletivos de Recaptação de Serotonina/administração & dosagem , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Fatores Socioeconômicos , Trazodona/administração & dosagem , Trazodona/uso terapêutico , Estados UnidosRESUMO
The chemistry, pharmacokinetics, biochemistry and pharmacology, clinical trials, adverse effects, FDA-approved indications, and availability and cost of trazodone hydrochloride, a triazolopyridine antidepressant, are reviewed. Trazodone is nearly completely absorbed after oral administration; although food delays absorption and reduces peak serum concentration, total area under the plasma concentration-time curve is not altered. Trazodone has biphasic elimination, with a redistribution half-life of about one hour and an elimination half-life of 10-12 hours. Trazodone is nearly completely metabolized hepatically by hydroxylation and oxidation to metabolites that are probably inactive. Trazodone is less potent but more selective than conventional tricyclic antidepressants; at low doses, trazodone acts as a serotonin antagonist, while at high doses it acts as a serotonin agonist. Trazodone has been compared with imipramine, amitriptyline, desipramine, and placebo in controlled clinical trials and found to be an effective antidepressant. Trazodone causes significantly fewer anticholinergic side effects than does imipramine. Trazodone has few cardiovascular side effects. In patients ingesting toxic amounts of trazodone, no deaths have been reported unless other drugs were present or ingested concomitantly. The usual adult daily dose of trazodone hydrochloride is 150-400 mg given in two divided doses. Trazodone is an effective antidepressant with a low incidence of serious adverse effects. It may be particularly useful in certain depressed patients who are intolerant of anticholinergic effects of other antidepressants, have cardiac conduction disturbances, or who do not respond to treatment with tricyclic antidepressants and in whom electroshock therapy is contraindicted.